Cyclic compounds (13)
Carboxylic acids (1)
Organic acids (1)
Sigma Aldrich (3)
AK Scientific (2)
TCI Chemicals (2)
Emtricitabine (143491-57-0, 143491-54-7)
Emtricitabine (commonly called FTC, systematic name 2',3'-dideoxy-5-fluoro-3'-thiacytidine), with trade name Emtriva (formerly Coviracil), is a nucleoside reverse transcriptase inhibitor (NRTI) for the prevention and treatment of HIV infection in adults and children. Emtricitabine is also marketed in a fixed-dose combination with tenofovir (Viread) under the brand name Truvada. A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S.
tegafur (82294-77-7, 17902-23-7)
Ftorafur · FT 207 · 1-(Tetrahydro-2-furanyl)-5-fluorouracil
Tegafur (INN, BAN, USAN) is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU.
Flomoxef (INN) is an oxacephem antibiotic. It has been classified as second-generation and fourth-generation.
Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV infection. Elvucitabine belongs to a class (group) of HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs).
Dexelvucitabine is a failed experimental agent for the management of HIV infection. Dexelvucitabine is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. It was found to inhibit HIV-1 replication in vitro and during Phase II clinical trials, it was found to decrease mean viral load in patients with HIV.
Fialuridine, or 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU), is a nucleoside analogue that was investigated as a potential therapy for hepatitis B virus infection. In a 1993 clinical study at the NIH, unexpected toxicity led to the death of 5 out of 15 patients from liver failure associated with lactic acidosis; two further participants required liver transplantation. This toxicity was unusual in that it was not predicted by animal studies.
Cefazaflur (INN) is a first-generation cephalosporin antibiotic.
Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV. It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.